logo
[breadcrumb_custom]

Tag: RLAY Stock

News

RLAY’s Market Whiplash: -25.79% YTD Decline, -9.12% Plunge in 30 Days

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a loss of -25.79%.However, over the last six months, we can see a stronger performance of -13.91%. Over the last 30 days, the price of RLAY has leaped by -9.12%. And in the last five days, it has fallen by -19.51%. Relay Therapeutics Inc had a pretty Dodgy run when it comes to the market performance. Over

Stock

Relay Therapeutics Inc: Navigating Market Fluctuations with a 1.28B Market Cap

Relay Therapeutics Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $19.54 on 02/24/23, while the lowest price for the same duration was marked at $5.95 on 10/27/23. 52-week price history of RLAY Stock A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Relay Therapeutics Inc’s current trading price is -48.77% away from its 52-week high, while its distance from the 52-week low is 68.24%. The stock’s price range during this period has spanned from $5.95 to $19.54. In the Healthcare

Stock

Relay Therapeutics Inc (RLAY) Stock: A Year of Stock Market Dynamics

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Relay Therapeutics Inc’s current trading price is -49.39% away from its 52-week high, while its distance from the 52-week low is 66.22%. The stock’s price range over this period has fluctuated between $5.95 and $19.54. The company, operating within the financial sector, had a trading volume of approximately 2.37 million for the day, which was noticeably higher than the average daily share volume of 1.01 million over the last 3 months. Relay Therapeutics Inc’s market performance has